


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:52:44Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406994" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406994</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Blood Press Monit</journal-id><journal-id journal-id-type="iso-abbrev">Blood Press Monit</journal-id><journal-id journal-id-type="pmc-domain-id">2035</journal-id><journal-id journal-id-type="pmc-domain">lwwopen</journal-id><journal-id journal-id-type="publisher-id">BPMJ</journal-id><journal-title-group><journal-title>Blood Pressure Monitoring</journal-title></journal-title-group><issn pub-type="ppub">1359-5237</issn><issn pub-type="epub">1473-5725</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Lippincott Open Access</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406994</article-id><article-id pub-id-type="pmcid-ver">PMC12406994.1</article-id><article-id pub-id-type="pmcaid">12406994</article-id><article-id pub-id-type="pmcaiid">12406994</article-id><article-id pub-id-type="pmid">40762523</article-id><article-id pub-id-type="doi">10.1097/MBP.0000000000000766</article-id><article-id pub-id-type="publisher-id">BPMJ-24-144</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Clinical Methods and Pathophysiology</subject></subj-group></article-categories><title-group><article-title>Association of phenotypic age acceleration with the risk of all-cause and cardiovascular disease-related mortality in patients with hypertension</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Yu</surname><given-names initials="Q">Qiao</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shang</surname><given-names initials="B">Baoling</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sun</surname><given-names initials="H">Haijiao</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jiang</surname><given-names initials="W">Wei</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cao</surname><given-names initials="Q">Qian</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zou</surname><given-names initials="X">Xu</given-names></name><xref rid="aff4" ref-type="aff">d</xref></contrib><aff id="aff1"><label>a</label>Department of Cardiac Function Center</aff><aff id="aff2"><label>b</label>Linnan Deng&#8217;s School of Internal Medicine Inheritance Studio</aff><aff id="aff3"><label>c</label>Research Department</aff><aff id="aff4"><label>d</label>Cardiovascular Department, The Second Clinical College of Guangzhou University of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong Province, China</aff></contrib-group><author-notes><corresp id="c1">Correspondence to Xu Zou, MM, Cardiovascular Department, The Second Clinical College of Guangzhou University of Chinese Medicine, No. 108 Xianhu Street, Danan Road, Yuxiu District, Guangzhou, Guangdong Province 510115, China, Tel: +86 020 81887233; e-mail: <email xlink:href="zouxucardiovascular@outlook.com">zouxucardiovascular@outlook.com</email></corresp></author-notes><pub-date pub-type="epub"><day>05</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2025</year></pub-date><volume>30</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">496166</issue-id><fpage>222</fpage><lpage>233</lpage><history><date date-type="received"><day>18</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>08</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 The Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND)</ext-link>, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="bpmj-30-222.pdf"/><self-uri xlink:href="bpmj-30-222.pdf"/><abstract><sec><title>Objective</title><p>To investigate the associations between phenotypic age acceleration (PhenoAgeAccel) and all-cause/cardiovascular disease (CVD)-related mortality in hypertensive patients.</p></sec><sec><title>Methods</title><p>We analyzed data from 14 352 hypertensive adults (&#8805;20 years) in the National Health and Nutrition Examination Survey 1999&#8211;2010. PhenoAge was calculated using chronological age and nine biomarkers (albumin, creatinine, glucose, C-reactive protein, lymphocyte%, mean cell volume, red blood cell distribution width, alkaline phosphatase, and white blood cell count). PhenoAgeAccel was derived as residuals from linear regression of PhenoAge on chronological age. Participants were stratified by PhenoAge [&lt;46.6792 (792&#8211;64.774 (T1&#8211;T2), &#8805;64.774 (&#8805;T2)] and PhenoAgeAccel [&lt;&#8722;4.3382 (382&#8211;0.9896 (T1&#8211;T2), &#8805;0.9896 (&#8805;T2)] tertiles. Cox proportional hazards models assessed mortality risks.</p></sec><sec><title>Results</title><p>Increased all-cause mortality was observed in hypertensive patients with PhenoAge in T1&#8211;T2 group [hazards ratio = 4.38, 95% confidence interval (CI): 3.79&#8211;5.06] and greater than or equal to T2 (hazards ratio = 14.22, 95% CI: 12.32&#8211;16.43). Significant association between PhenoAgeAccel greater than or equal to T2 and increased risk of all-cause mortality in hypertensive patients (hazards ratio = 1.41, 95% CI: 1.29&#8211;1.55) was identified. PhenoAge of T1&#8211;T2 (hazards ratio = 5.15, 95% CI: 3.86&#8211;6.86) and greater than or equal to T2 (hazards ratio = 20.20, 95% CI: 14.98&#8211;27.26) were related to increased CVD-related mortality in hypertensive patients. Increased risk of CVD-related mortality was identified in hypertensive patients with PhenoAgeAccel greater than or equal to T2 (hazards ratio = 1.35, 95% CI: 1.17&#8211;1.56).</p></sec><sec><title>Conclusion</title><p>Elevated PhenoAge and PhenoAgeAccel significantly predict higher all-cause and CVD mortality in hypertension, supporting clinical risk stratification.</p></sec></abstract><kwd-group><kwd>all-cause mortality</kwd><kwd>CVD-related mortality</kwd><kwd>phenotypic age</kwd><kwd>phenotypic age acceleration</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>SDC</meta-name><meta-value>T</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>The prevalence of hypertension in the adult population is high, approximately 30%, and the proportion of individuals with hypertension increases significantly as age advances [<xref rid="R1" ref-type="bibr">1</xref>]. Currently, approximately 1.16 billion adults worldwide have hypertension. Compared with the general population, individuals with hypertension are at a higher risk of all-cause and cardiovascular disease (CVD)&#8211;related mortality [<xref rid="R2" ref-type="bibr">2</xref>]. The prevalence of hypertension has become a significant public health concern and healthcare burden in both developed and developing countries [<xref rid="R3" ref-type="bibr">3</xref>]. Identifying more relevant biomarkers associated with the prognosis of hypertensive patients is of significant clinical value.</p><p>With advancing age, the prevalence of high blood pressure also increases gradually [<xref rid="R4" ref-type="bibr">4</xref>]. Aging is one of the major risk factors for chronic diseases, including hypertension [<xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R6" ref-type="bibr">6</xref>]. While chronological age can be easily determined based on birth date, there is considerable interindividual variability in functional and physiological integrity during the aging process. This variability leads to individuals of the same chronological age exhibiting divergent biological ages [<xref rid="R7" ref-type="bibr">7</xref>]. Utilizing previously established candidate hallmarks of aging in biological processes appears to provide more accurate predictions for functional decline, health span, and ultimately mortality compared with relying solely on chronological age [<xref rid="R8" ref-type="bibr">8</xref>]. A novel multisystem-based measure of aging, known as phenotypic age (PhenoAge), has been developed and extensively validated as a reliable indicator of biological aging in recent research studies [<xref rid="R9" ref-type="bibr">9</xref>]. Phenotypic age acceleration (PhenoAgeAccel) is defined as the difference between PhenoAge and chronological age, reflecting the degree of deviation between an individual&#8217;s biological age and their actual age. It quantifies the disparity between biological aging and chronological aging and has been validated as a robust biomarker for distinguishing susceptibility to various health outcomes [<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R11" ref-type="bibr">11</xref>]. A recent study has found that another aging biomarker, methylation-based epigenetic age acceleration, is associated with the risk of developing hypertension [<xref rid="R12" ref-type="bibr">12</xref>]. Therefore, we suspected that PhenoAgeAccel might have a potential effect on the mortality risk in hypertensive patients.</p><p>In this study, we intended to explore the association between PhenoAgeAccel and all-cause and CVD-related mortality in hypertensive patients based on the National Health and Nutrition Examination Survey (NHANES) database. The NHANES, conducted by the Centers for Disease Control and Prevention&#8217;s National Center for Health Statistics, has been monitoring the nation&#8217;s nutrition and health for over five decades. It gathers data that can be acquired through direct physical examination, clinical and laboratory tests, personal interviews, and related measurement procedures (<ext-link xlink:href="https://www.cdc.gov/nchs/nhanes/about/?CDC_AAref_Val=https://www.cdc.gov/nchs/nhanes/about_nhanes.htm" ext-link-type="uri">https://www.cdc.gov/nchs/nhanes/about/?CDC_AAref_Val=https://www.cdc.gov/nchs/nhanes/about_nhanes.htm</ext-link>) [<xref rid="R13" ref-type="bibr">13</xref>]. Subgroup analysis was performed in different genders, BMI, and complication groups to verify the results in different populations.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study design and population</title><p>In this cohort study, we identified 17 582 hypertensive patients aged greater than or equal to 20 years from the NHANES 1999&#8211;2010. Hypertension was defined based on self-reported physician-diagnosed hypertension, systolic blood pressure (SBP) greater than or equal to 130&#8197;mmHg or diastolic blood pressure greater than or equal to 80&#8197;mmHg [<xref rid="R14" ref-type="bibr">14</xref>], or the use of antihypertensive medications. Participants without complete survival information were excluded (<italic toggle="yes">n</italic>&#8197;=&#8197;15). Participants without data on calculating PhenoAge including albumin (<italic toggle="yes">n</italic>&#8197;=&#8197;1877), creatinine (<italic toggle="yes">n</italic>&#8197;=&#8197;1), C-reactive protein (CRP) (<italic toggle="yes">n</italic>&#8197;=&#8197;6), alkaline phosphatase (ALP) (<italic toggle="yes">n</italic>&#8197;=&#8197;2), white blood cell count (WBC) (<italic toggle="yes">n</italic>&#8197;=&#8197;34), and lymphocyte percent (<italic toggle="yes">n</italic>&#8197;=&#8197;57) were excluded. In addition, those without information of CVD (<italic toggle="yes">n</italic>&#8197;=&#8197;3), dyslipidemia (<italic toggle="yes">n</italic>&#8197;=&#8197;6), cancer (<italic toggle="yes">n</italic>&#8197;=&#8197;21), arthritis (<italic toggle="yes">n</italic>&#8197;=&#8197;31), smoking (<italic toggle="yes">n</italic>&#8197;=&#8197;13), marriage (<italic toggle="yes">n</italic>&#8197;=&#8197;242), education (<italic toggle="yes">n</italic>&#8197;=&#8197;23), BMI (<italic toggle="yes">n</italic>&#8197;=&#8197;394), and energy (<italic toggle="yes">n</italic>&#8197;=&#8197;505) were excluded. Finally, 14 352 hypertension patients were analyzed. The screening process of participants in this study is exhibited in Fig. <xref rid="F1" ref-type="fig">1</xref>.</p><fig position="float" id="F1" orientation="portrait"><label>Fig. 1</label><caption><p>The screening process of the participants analyzed in our study. ALP, alkaline phosphatase; CRP, C-reactive protein; CVD, cardiovascular disease; NHANES, National Health and Nutrition Examination Survey; WBC, white blood cell count.</p></caption><graphic position="float" orientation="portrait" xlink:href="bpmj-30-222-g001.jpg"/></fig></sec><sec><title>Potential covariates and definitions</title><p>Gender (female or male), race (non-Hispanic White, non-Hispanic Black, Mexican American, or other races), poverty-to-income ratio (PIR) (&lt;1, &#8805;1, or unknown), marital status (married/living with partner or widowed/divorced/separated/never married), education (below high school, high school/General Educational Development or equivalent, or above high school), BMI (&lt;25, 25&#8211;30, or &#8805;30&#8197;kg/m<sup>2</sup>), physical activity [&lt;600 metabolic equivalent (MET) &#215; min/week, &#8805;600 MET &#215; min/week, or unknown], drinking (yes, no, or unknown), smoking (yes, no, or unknown), protein (% kcal), carbohydrate (% kcal), total fat (% kcal), the estimated glomerular filtration rate (eGFR) (&lt;60 or &#8805;60&#8197;ml/min/1.73 m<sup>2</sup>), diabetes (yes or no), dyslipidemia (yes or no), CVD (yes or no), cancer (yes or no), arthritis (yes or no), and medication for hypertension were variables analyzed in this study. (The data of physical activity in the database 1999&#8211;2006 was identified based on the database questionnaire &#8216;Physical Activity Questionnaire for International Adult Fitness&#8217; [<xref rid="R14" ref-type="bibr">14</xref>] (PADTIMES-of times did activity in past 30 days; PADDURAT-average duration of activity (minutes); and PADMETS-MET score for activity. Physical activity (PA) data between 2007 and 2010 were identified according to the PAQ655-days vigorous recreational activities in the database questionnaire; PAD660-min vigorous recreational activities; PAQ640-number of days walk or bicycle; PAD645-min walk/bicycle for transportation; PAQ670-days moderate recreational activities; PAD675-min moderate recreational activities; PAQ610-days vigorous work; PAD615-min vigorous-intensity work; PAQ625-number of days moderate work; and PAD630-min moderate-intensity work for calculations. Energy expenditure (MET &#215; min/week) = recommended MET &#215; daily duration of corresponding activity (min) &#215; weekly frequency of corresponding activity. PA = PADTIMES &#215; PADDURAT &#215; PADMETS/4 (year: 2005&#8211;2006); PA = PAQ655 &#215; PAD660&#8197;&#215;&#8197;8 + PAQ640 &#215; PAD645&#8197;&#215;&#8197;4 + PAQ670 &#215; PAD675&#8197;&#215;&#8197;4 + PAQ610 &#215; PAD615&#8197;&#215;&#8197;8 + PAQ625 &#215; PAD630&#8197;&#215;&#8197;4 (year: 2007&#8211;2010). If the answer in PAQ605, PAQ620, PAQ635, PAQ650, PAQ665 was &#8216;no&#8217;, the corresponding activity was 0. PA was divided into &lt;600 MET &#215; min/week and &#8805;600 MET &#215; min/week.) and missing values were defined as unknown. Estimated glomerular filtration rate chronic kidney disease-epidemiology collaboration (ml/min/1.73 m<sup>2</sup>)&#8197;=&#8197;141 &#215; min (Scr/<italic toggle="yes">&#954;</italic>, 1) <italic toggle="yes">&#945;</italic> &#215; max (Scr/&#954;, 1) &#8722;1.029&#8197;&#215;&#8197;0.993 age &#215; 1.108 (if female)&#8197;&#215;&#8197;1.159 (if black), <italic toggle="yes">&#954;</italic> is 0.7 for females and 0.9 for males, <italic toggle="yes">&#945;</italic> is &#8722;0.329 for females and &#8722;0.411 for males, min indicates the minimum of Scr/<italic toggle="yes">&#954;</italic> or 1, and max indicates the maximum of Scr/<italic toggle="yes">&#954;</italic> or 1 [<xref rid="R15" ref-type="bibr">15</xref>]. Medication for hypertension included angiotensin-converting enzyme inhibitors, beta-adrenergic blocking agents, calcium channel blocking agents, and diuretics. On the basis of the types of medication for hypertension, all participants were divided into the no use group, only one type group, greater than or equal to two types group, and unknown group.</p></sec><sec><title>Main variables</title><p>PhenoAge and PhenoAgeAccel were the main variables. The calculation of PhenoAge involves nine biomarkers, including albumin, creatinine, glucose, CRP, lymphocyte percentage, mean cell volume, red blood cell distribution width, ALP, and WBC, as well as chronological age [<xref rid="R16" ref-type="bibr">16</xref>]. The calculation equation was as follows (Supplementary Table S1, Supplemental digital content 1, <ext-link xlink:href="https://links.lww.com/BPMJ/A247" ext-link-type="uri">https://links.lww.com/BPMJ/A247</ext-link>).</p><disp-formula><mml:math id="M1" overflow="scroll"><mml:mstyle displaystyle="true"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mstyle displaystyle="true"><mml:mrow><mml:mtext/></mml:mrow><mml:mtext/><mml:mrow><mml:mtext/><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">y</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mtext/></mml:mrow><mml:mtext/><mml:mrow><mml:mtext/><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mn>141.50</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mo>&#8722;</mml:mo><mml:mn>0.00553</mml:mn><mml:mo>&#215;</mml:mo><mml:mrow><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>&#8722;</mml:mo><mml:mi>M</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mn>0.09165</mml:mn></mml:mfrac></mml:mstyle></mml:mtd></mml:mtr></mml:mtable></mml:mstyle></mml:math></disp-formula><p>where</p><disp-formula><mml:math id="M2" overflow="scroll"><mml:mstyle displaystyle="true"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mstyle displaystyle="true"><mml:mrow><mml:mtext/></mml:mrow><mml:mtext/><mml:mrow><mml:mtext/></mml:mrow><mml:mi>M</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>&#8722;</mml:mo><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mn>1.51714</mml:mn><mml:mo>&#215;</mml:mo><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>x</mml:mi><mml:mi>b</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mn>0.0076927</mml:mn></mml:mfrac><mml:mo>)</mml:mo></mml:mrow></mml:mstyle></mml:mtd></mml:mtr></mml:mtable></mml:mstyle></mml:math></disp-formula><p>and</p><disp-formula><mml:math id="M3" overflow="scroll"><mml:mstyle displaystyle="true"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mrow><mml:mtext/></mml:mrow><mml:mtext/><mml:mrow><mml:mtext/><mml:mi mathvariant="normal">x</mml:mi><mml:mi mathvariant="normal">b</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mo>&#8722;</mml:mo><mml:mn>19.907</mml:mn><mml:mo>&#8722;</mml:mo><mml:mn>0.0336</mml:mn><mml:mo>&#215;</mml:mo><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>b</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mn>0.0095</mml:mn><mml:mtext/></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>&#215;</mml:mo><mml:mi>c</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mo>+</mml:mo><mml:mn>0.1953</mml:mn><mml:mo>&#215;</mml:mo><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>u</mml:mi><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mo>+</mml:mo><mml:mn>0.0954</mml:mn><mml:mtext/></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>&#215;</mml:mo><mml:mrow><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#8722;</mml:mo><mml:mn>0.0120</mml:mn><mml:mo>&#215;</mml:mo><mml:mi>l</mml:mi><mml:mi>y</mml:mi><mml:mi>m</mml:mi><mml:mi>p</mml:mi><mml:mi>h</mml:mi><mml:mi>o</mml:mi><mml:mi>c</mml:mi><mml:mi>y</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mtext/><mml:mi>p</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mtext/></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>+</mml:mo><mml:mn>0.0268</mml:mn><mml:mo>&#215;</mml:mo><mml:mrow><mml:mtext/></mml:mrow><mml:mtext/><mml:mrow><mml:mtext/><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mtext/></mml:mrow><mml:mtext/><mml:mrow><mml:mtext/><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mtext/></mml:mrow><mml:mtext/><mml:mrow><mml:mtext/><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mo>+</mml:mo><mml:mn>0.3306</mml:mn><mml:mo>&#215;</mml:mo><mml:mi>R</mml:mi><mml:mi>D</mml:mi><mml:mi>W</mml:mi><mml:mtext/></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>+</mml:mo><mml:mn>0.00188</mml:mn><mml:mo>&#215;</mml:mo><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>k</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mtext/><mml:mi>p</mml:mi><mml:mi>h</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>p</mml:mi><mml:mi>h</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mo>+</mml:mo><mml:mn>0.0554</mml:mn><mml:mtext/></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>&#215;</mml:mo><mml:mi>W</mml:mi><mml:mi>B</mml:mi><mml:mi>C</mml:mi><mml:mtext/><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mn>0.0804</mml:mn><mml:mo>&#215;</mml:mo><mml:mi>c</mml:mi><mml:mi>h</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mtext/><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mtext/></mml:mtd></mml:mtr></mml:mtable></mml:mstyle></mml:math></disp-formula><p>PhenoAge was divided into less than 46.6792 (&lt;T1) group, 46.6792&#8211;64.7740 (T1&#8211;T2) group, and greater than or equal to 64.7740 (&#8805;T2) group based on tertiles.</p><p>PhenoAgeAccel is the regression residual of chronological age on biological age, with its negative value indicating that an individual has a younger PhenoAge [i.e. whether a person&#8217;s biological age is older (&#8805;0) or younger (&lt;0) than expected, based on his/her chronological age].</p><p>PhenoAgeAccel was divided into less than &#8722;4.3382 (&lt;T1) group, &#8722;4.3382 to 0.9896 (T1&#8211;T2) group, and greater than or equal to 0.9896 (&#8805;T2) group based on tertiles.</p></sec><sec><title>Outcome variable</title><p>Mortality information was ascertained by linkage to in the National Death Index records through 31 December 2019. All data in this study are publicly available (<ext-link xlink:href="https://www.cdc.gov/nchs/data-linkage/mortality.htm" ext-link-type="uri">https://www.cdc.gov/nchs/data-linkage/mortality.htm</ext-link>). Among them, deaths because of any cause were classified as all-cause mortality. The causes of death because of &#8216;disease of heart (I00&#8211;I09, I11, I13, I20&#8211;I51)&#8217; or &#8216;cerebrovascular diseases (I60&#8211;I69)&#8217; were regarded as CVD-related mortality.</p></sec><sec><title>Statistical analysis</title><p>Continuous measurement data were described as mean &#177; SE, and weighted two-sample <italic toggle="yes">t</italic> test was used for comparison between multiple groups. The enumeration data were described as numbers and ratios [<italic toggle="yes">n</italic> (%)], and Rao&#8211;Scott Chi-square test was used for comparison between groups. The confounding factors associated with all-cause or CVD-related mortality in hypertensive patients were identified via univariable Cox regression, and variables with a <italic toggle="yes">P</italic> value less than 0.05 were considered as confounding factors. Univariable and multivariable Cox models were applied to explore the association between PhenoAge or PhenoAgeAccel and all-cause and CVD-related mortality in hypertensive patients. Subgroup analysis was performed according to gender, BMI, and comorbidities. The hazard ratio and 95% confidence interval (CI) were calculated. Statistical analysis was performed using R version 4.2.3 (2023-03-15ucrt). <italic toggle="yes">P</italic> value less than 0.05 was regarded as statistically significant.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Comparisons of the characteristics of participants who survived or died</title><p>The all-cause mortality rate in all participants was 32.17%, and 1555 participants died of CVD. The mean PhenoAge in the death group was older than the survival group (68.16 vs. 44.91 years; <italic toggle="yes">P</italic>&#8197;&lt;&#8197;0.001). The mean of PhenoAge in participants in the alive group was lower than the death group (Fig. <xref rid="F2" ref-type="fig">2</xref>). The mean levels of PhenoAgeAccel in the alive group were also lower than the death group (Fig. <xref rid="F3" ref-type="fig">3</xref>). The percentage of participants with PhenoAge greater than or equal to T2 in the death group was higher than the survival group (60.00 vs. 10.21%; <italic toggle="yes">P</italic>&#8197;&lt;&#8197;0.001). The mean PhenoAgeAccel in the death group was 1.88, while in the survival group was &#8722;1.96 (<italic toggle="yes">P</italic>&#8197;&lt;&#8197;0.001). The percentage of participants with PhenoAgeAccel greater than or equal to T2 in the death group was higher than the survival group (40.50 vs. 24.35%; <italic toggle="yes">P</italic>&#8197;&lt;&#8197;0.001) (Tables <xref rid="T1" ref-type="table">1</xref> and <xref rid="T2" ref-type="table">2</xref>). The mean of PhenoAge in participants in the non-CVD death group was lower than the CVD death group (Fig. <xref rid="F4" ref-type="fig">4</xref>). The mean levels of PhenoAgeAccel in the non-CVD death group were also lower than the CVD death group (Fig. <xref rid="F5" ref-type="fig">5</xref>).</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>The related information of participants</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Total (<italic toggle="yes">n</italic>&#8197;=&#8197;14 352)</th><th align="center" rowspan="1" colspan="1">Survival group (<italic toggle="yes">n</italic>&#8197;=&#8197;9735)</th><th align="center" rowspan="1" colspan="1">Death group (<italic toggle="yes">n</italic>&#8197;=&#8197;4617)</th><th align="center" rowspan="1" colspan="1">Statistics</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Phenotypic age, mean (&#177;SE)</td><td align="center" rowspan="1" colspan="1">50.69 (&#177;0.32)</td><td align="center" rowspan="1" colspan="1">44.91 (&#177;0.29)</td><td align="center" rowspan="1" colspan="1">68.16 (&#177;0.36)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic>&#8197;=&#8197;64.095</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="4" rowspan="1">Phenotypic age, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">&#967;</italic>&#178; = 1696.020</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">4784 (44.72)</td><td align="center" rowspan="1" colspan="1">4524 (56.34)</td><td align="center" rowspan="1" colspan="1">260 (9.65)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">4784 (32.68)</td><td align="center" rowspan="1" colspan="1">3632 (33.45)</td><td align="center" rowspan="1" colspan="1">1152 (30.35)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">4784 (22.60)</td><td align="center" rowspan="1" colspan="1">1579 (10.21)</td><td align="center" rowspan="1" colspan="1">3205 (60.00)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Phenotypic age acceleration, mean (&#177;SE)</td><td align="center" rowspan="1" colspan="1">&#8722;1.01 (&#177;0.10)</td><td align="center" rowspan="1" colspan="1">&#8722;1.96 (&#177;0.09)</td><td align="center" rowspan="1" colspan="1">1.88 (&#177;0.21)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic>&#8197;=&#8197;17.205</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="4" rowspan="1">Phenotypic age acceleration, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">&#967;</italic>&#178; = 116.611</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">4784 (36.45)</td><td align="center" rowspan="1" colspan="1">3515 (38.97)</td><td align="center" rowspan="1" colspan="1">1269 (28.86)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">4784 (35.18)</td><td align="center" rowspan="1" colspan="1">3460 (36.68)</td><td align="center" rowspan="1" colspan="1">1324 (30.63)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">4784 (28.37)</td><td align="center" rowspan="1" colspan="1">2760 (24.35)</td><td align="center" rowspan="1" colspan="1">2024 (40.50)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Exposure-related biomarkers</td></tr><tr><td align="left" rowspan="1" colspan="1">Albumin (g/L), mean (&#177;SE)</td><td align="center" rowspan="1" colspan="1">42.65 (&#177;0.06)</td><td align="center" rowspan="1" colspan="1">42.93 (&#177;0.06)</td><td align="center" rowspan="1" colspan="1">41.79 (&#177;0.08)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic>&#8197;=&#8197;&#8722;18.086</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (&#181;mol/L), mean (&#177;SE)</td><td align="center" rowspan="1" colspan="1">82.27 (&#177;0.47)</td><td align="center" rowspan="1" colspan="1">78.61 (&#177;0.37)</td><td align="center" rowspan="1" colspan="1">93.32 (&#177;1.24)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic>&#8197;=&#8197;12.000</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">ALP (U/L), mean (&#177;SE)</td><td align="center" rowspan="1" colspan="1">72.66 (&#177;0.44)</td><td align="center" rowspan="1" colspan="1">71.01 (&#177;0.40)</td><td align="center" rowspan="1" colspan="1">77.63 (&#177;0.73)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic>&#8197;=&#8197;10.349</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Glucose (mmol/L), mean (&#177;SE)</td><td align="center" rowspan="1" colspan="1">5.65 (&#177;0.02)</td><td align="center" rowspan="1" colspan="1">5.50 (&#177;0.02)</td><td align="center" rowspan="1" colspan="1">6.10 (&#177;0.05)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic>&#8197;=&#8197;11.819</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">WBC (1000/&#181;l), mean (&#177;SE)</td><td align="center" rowspan="1" colspan="1">7.32 (&#177;0.03)</td><td align="center" rowspan="1" colspan="1">7.28 (&#177;0.03)</td><td align="center" rowspan="1" colspan="1">7.46 (&#177;0.05)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic>&#8197;=&#8197;3.198</td><td align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">LYM% (%), mean (&#177;SE)</td><td align="center" rowspan="1" colspan="1">29.54 (&#177;0.11)</td><td align="center" rowspan="1" colspan="1">30.28 (&#177;0.12)</td><td align="center" rowspan="1" colspan="1">27.29 (&#177;0.16)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic>&#8197;=&#8197;&#8722;15.671</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">MCV (fl), mean (&#177;SE)</td><td align="center" rowspan="1" colspan="1">90.16 (&#177;0.11)</td><td align="center" rowspan="1" colspan="1">89.68 (&#177;0.11)</td><td align="center" rowspan="1" colspan="1">91.64 (&#177;0.13)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic>&#8197;=&#8197;16.140</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">RDW (%), mean (&#177;SE)</td><td align="center" rowspan="1" colspan="1">12.81 (&#177;0.01)</td><td align="center" rowspan="1" colspan="1">12.68 (&#177;0.01)</td><td align="center" rowspan="1" colspan="1">13.22 (&#177;0.02)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic>&#8197;=&#8197;24.331</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">CRP (mg/dl), mean (&#177;SE)</td><td align="center" rowspan="1" colspan="1">0.47 (&#177;0.01)</td><td align="center" rowspan="1" colspan="1">0.44 (&#177;0.01)</td><td align="center" rowspan="1" colspan="1">0.59 (&#177;0.02)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic>&#8197;=&#8197;8.273</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years), mean (&#177;SE)</td><td align="center" rowspan="1" colspan="1">54.04 (&#177;0.28)</td><td align="center" rowspan="1" colspan="1">49.34 (&#177;0.27)</td><td align="center" rowspan="1" colspan="1">68.24 (&#177;0.30)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic>&#8197;=&#8197;63.552</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="6" rowspan="1">Other variables</td></tr><tr><td align="left" colspan="4" rowspan="1">Gender, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">&#967;</italic>&#178; = 1.398</td><td align="center" rowspan="1" colspan="1">0.240</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Female</td><td align="center" rowspan="1" colspan="1">6840 (48.17)</td><td align="center" rowspan="1" colspan="1">4785 (47.90)</td><td align="center" rowspan="1" colspan="1">2055 (48.99)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Male</td><td align="center" rowspan="1" colspan="1">7512 (51.83)</td><td align="center" rowspan="1" colspan="1">4950 (52.10)</td><td align="center" rowspan="1" colspan="1">2562 (51.01)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Race, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">&#967;</italic>&#178; = 30.254</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Non-Hispanic White</td><td align="center" rowspan="1" colspan="1">7547 (74.21)</td><td align="center" rowspan="1" colspan="1">4647 (72.07)</td><td align="center" rowspan="1" colspan="1">2900 (80.66)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Non-Hispanic Black</td><td align="center" rowspan="1" colspan="1">3021 (11.51)</td><td align="center" rowspan="1" colspan="1">2169 (11.93)</td><td align="center" rowspan="1" colspan="1">852 (10.24)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Mexican American</td><td align="center" rowspan="1" colspan="1">2475 (5.65)</td><td align="center" rowspan="1" colspan="1">1875 (6.48)</td><td align="center" rowspan="1" colspan="1">600 (3.14)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Other races</td><td align="center" rowspan="1" colspan="1">1309 (8.64)</td><td align="center" rowspan="1" colspan="1">1044 (9.52)</td><td align="center" rowspan="1" colspan="1">265 (5.97)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">PIR, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">&#967;</italic>&#178; = 10.830</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;1</td><td align="center" rowspan="1" colspan="1">2310 (10.95)</td><td align="center" rowspan="1" colspan="1">1539 (10.40)</td><td align="center" rowspan="1" colspan="1">771 (12.62)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;1</td><td align="center" rowspan="1" colspan="1">10 908 (82.53)</td><td align="center" rowspan="1" colspan="1">7459 (83.57)</td><td align="center" rowspan="1" colspan="1">3449 (79.42)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Unknown</td><td align="center" rowspan="1" colspan="1">1134 (6.51)</td><td align="center" rowspan="1" colspan="1">737 (6.04)</td><td align="center" rowspan="1" colspan="1">397 (7.96)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Marriage, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">&#967;</italic>&#178; = 127.968</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Married/living with partner</td><td align="center" rowspan="1" colspan="1">8864 (66.09)</td><td align="center" rowspan="1" colspan="1">6375 (69.32)</td><td align="center" rowspan="1" colspan="1">2489 (56.32)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Widowed/divorced/separated/never married</td><td align="center" rowspan="1" colspan="1">5488 (33.91)</td><td align="center" rowspan="1" colspan="1">3360 (30.68)</td><td align="center" rowspan="1" colspan="1">2128 (43.68)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Education, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">&#967;</italic>&#178; = 163.612</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Below high school</td><td align="center" rowspan="1" colspan="1">4673 (21.07)</td><td align="center" rowspan="1" colspan="1">2761 (17.21)</td><td align="center" rowspan="1" colspan="1">1912 (32.72)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;High school/GED or equivalent</td><td align="center" rowspan="1" colspan="1">3566 (27.13)</td><td align="center" rowspan="1" colspan="1">2425 (26.82)</td><td align="center" rowspan="1" colspan="1">1141 (28.05)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Above high school</td><td align="center" rowspan="1" colspan="1">6113 (51.80)</td><td align="center" rowspan="1" colspan="1">4549 (55.97)</td><td align="center" rowspan="1" colspan="1">1564 (39.23)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Height (cm), mean (&#177;SE)</td><td align="center" rowspan="1" colspan="1">168.95 (&#177;0.12)</td><td align="center" rowspan="1" colspan="1">169.67 (&#177;0.14)</td><td align="center" rowspan="1" colspan="1">166.77 (&#177;0.17)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic>&#8197;=&#8197;&#8722;15.322</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight (kg), mean (&#177;SE)</td><td align="center" rowspan="1" colspan="1">85.71 (&#177;0.28)</td><td align="center" rowspan="1" colspan="1">87.26 (&#177;0.34)</td><td align="center" rowspan="1" colspan="1">81.04 (&#177;0.34)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic>&#8197;=&#8197;&#8722;14.613</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="4" rowspan="1">BMI (kg/m<sup>2</sup>), <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">&#967;</italic>&#178; = 33.684</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;25</td><td align="center" rowspan="1" colspan="1">3232 (23.13)</td><td align="center" rowspan="1" colspan="1">1932 (21.38)</td><td align="center" rowspan="1" colspan="1">1300 (28.44)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;25&#8211;30</td><td align="center" rowspan="1" colspan="1">5081 (34.73)</td><td align="center" rowspan="1" colspan="1">3363 (34.59)</td><td align="center" rowspan="1" colspan="1">1718 (35.16)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;30</td><td align="center" rowspan="1" colspan="1">6039 (42.14)</td><td align="center" rowspan="1" colspan="1">4440 (44.04)</td><td align="center" rowspan="1" colspan="1">1599 (36.41)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">PA, MET &#215; min/week, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">&#967;</italic>&#178; = 184.351</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;600</td><td align="center" rowspan="1" colspan="1">4549 (30.46)</td><td align="center" rowspan="1" colspan="1">3135 (30.68)</td><td align="center" rowspan="1" colspan="1">1414 (29.80)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;600</td><td align="center" rowspan="1" colspan="1">5727 (43.72)</td><td align="center" rowspan="1" colspan="1">4439 (48.13)</td><td align="center" rowspan="1" colspan="1">1288 (30.38)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Unknown</td><td align="center" rowspan="1" colspan="1">4076 (25.82)</td><td align="center" rowspan="1" colspan="1">2161 (21.18)</td><td align="center" rowspan="1" colspan="1">1915 (39.82)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Drinking, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic toggle="yes">&#967;</italic>&#178; = 156.720</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">4450 (27.82)</td><td align="center" rowspan="1" colspan="1">2838 (25.42)</td><td align="center" rowspan="1" colspan="1">1612 (35.06)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">7317 (56.98)</td><td align="center" rowspan="1" colspan="1">5445 (61.68)</td><td align="center" rowspan="1" colspan="1">1872 (42.77)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Unknown</td><td align="center" rowspan="1" colspan="1">2585 (15.20)</td><td align="center" rowspan="1" colspan="1">1452 (12.89)</td><td align="center" rowspan="1" colspan="1">1133 (22.17)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Smoking, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">&#967;</italic>&#178; = 201.716</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">7048 (49.50)</td><td align="center" rowspan="1" colspan="1">5169 (52.62)</td><td align="center" rowspan="1" colspan="1">1879 (40.07)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">7304 (50.50)</td><td align="center" rowspan="1" colspan="1">4566 (47.38)</td><td align="center" rowspan="1" colspan="1">2738 (59.93)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Protein (% kcal), mean (&#177;SE)</td><td align="center" rowspan="1" colspan="1">15.64 (&#177;0.06)</td><td align="center" rowspan="1" colspan="1">15.64 (&#177;0.07)</td><td align="center" rowspan="1" colspan="1">15.67 (&#177;0.09)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic>&#8197;=&#8197;0.379</td><td align="center" rowspan="1" colspan="1">0.706</td></tr><tr><td align="left" rowspan="1" colspan="1">Carbohydrate (% kcal) mean (&#177;SE)</td><td align="center" rowspan="1" colspan="1">48.67 (&#177;0.16)</td><td align="center" rowspan="1" colspan="1">48.42 (&#177;0.18)</td><td align="center" rowspan="1" colspan="1">49.41 (&#177;0.23)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic>&#8197;=&#8197;4.049</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Total fat (% kcal), mean (&#177;SE)</td><td align="center" rowspan="1" colspan="1">33.93 (&#177;0.13)</td><td align="center" rowspan="1" colspan="1">33.94 (&#177;0.14)</td><td align="center" rowspan="1" colspan="1">33.89 (&#177;0.18)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic>&#8197;=&#8197;&#8722;0.262</td><td align="center" rowspan="1" colspan="1">0.794</td></tr><tr><td align="left" colspan="4" rowspan="1">eGFR (ml/min), 1.73 m<sup>2</sup>, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">&#967;</italic>&#178; = 1106.223</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;60</td><td align="center" rowspan="1" colspan="1">1464 (7.28)</td><td align="center" rowspan="1" colspan="1">389 (2.86)</td><td align="center" rowspan="1" colspan="1">1075 (20.62)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;60</td><td align="center" rowspan="1" colspan="1">12 888 (92.72)</td><td align="center" rowspan="1" colspan="1">9346 (97.14)</td><td align="center" rowspan="1" colspan="1">3542 (79.38)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Diabetes, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">&#967;</italic>&#178; = 442.365</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">11 117 (83.00)</td><td align="center" rowspan="1" colspan="1">7954 (86.87)</td><td align="center" rowspan="1" colspan="1">3163 (71.31)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">3235 (17.00)</td><td align="center" rowspan="1" colspan="1">1781 (13.13)</td><td align="center" rowspan="1" colspan="1">1454 (28.69)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Dyslipidemia, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">&#967;</italic>&#178; = 34.583</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">2629 (18.54)</td><td align="center" rowspan="1" colspan="1">1890 (19.67)</td><td align="center" rowspan="1" colspan="1">739 (15.12)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">11 723 (81.46)</td><td align="center" rowspan="1" colspan="1">7845 (80.33)</td><td align="center" rowspan="1" colspan="1">3878 (84.88)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">CVD, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">&#967;</italic>&#178; = 988.398</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">11 744 (85.26)</td><td align="center" rowspan="1" colspan="1">8707 (91.36)</td><td align="center" rowspan="1" colspan="1">3037 (66.84)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">2608 (14.74)</td><td align="center" rowspan="1" colspan="1">1028 (8.64)</td><td align="center" rowspan="1" colspan="1">1580 (33.16)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Cancer, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">&#967;</italic>&#178; = 398.310</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">12 558 (87.98)</td><td align="center" rowspan="1" colspan="1">8919 (91.33)</td><td align="center" rowspan="1" colspan="1">3639 (77.86)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">1794 (12.02)</td><td align="center" rowspan="1" colspan="1">816 (8.67)</td><td align="center" rowspan="1" colspan="1">978 (22.14)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Arthritis, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">&#967;</italic>&#178; = 551.806</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">9054 (65.94)</td><td align="center" rowspan="1" colspan="1">6732 (71.48)</td><td align="center" rowspan="1" colspan="1">2322 (49.20)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">5298 (34.06)</td><td align="center" rowspan="1" colspan="1">3003 (28.52)</td><td align="center" rowspan="1" colspan="1">2295 (50.80)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Medication for hypertension, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">&#967;</italic><sup>2</sup>&#8197;=&#8197;658.807</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No use</td><td align="center" rowspan="1" colspan="1">5938 (46.58)</td><td align="center" rowspan="1" colspan="1">4766 (52.97)</td><td align="center" rowspan="1" colspan="1">1172 (27.30)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Only one type</td><td align="center" rowspan="1" colspan="1">3095 (20.22)</td><td align="center" rowspan="1" colspan="1">1871 (18.50)</td><td align="center" rowspan="1" colspan="1">1224 (25.43)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;ACE inhibitor</td><td align="center" rowspan="1" colspan="1">1013 (32.82)</td><td align="center" rowspan="1" colspan="1">679 (35.63)</td><td align="center" rowspan="1" colspan="1">334 (26.65)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Beta-adrenergic blocking agents</td><td align="center" rowspan="1" colspan="1">875 (30.87)</td><td align="center" rowspan="1" colspan="1">542 (32.03)</td><td align="center" rowspan="1" colspan="1">333 (28.34)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Calcium channel blocking agents</td><td align="center" rowspan="1" colspan="1">633 (17.51)</td><td align="center" rowspan="1" colspan="1">299 (13.70)</td><td align="center" rowspan="1" colspan="1">334 (25.89)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Diuretics</td><td align="center" rowspan="1" colspan="1">574 (18.79)</td><td align="center" rowspan="1" colspan="1">351 (18.65)</td><td align="center" rowspan="1" colspan="1">223 (19.11)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;2 types</td><td align="center" rowspan="1" colspan="1">3903 (23.90)</td><td align="center" rowspan="1" colspan="1">2085 (18.85)</td><td align="center" rowspan="1" colspan="1">1818 (39.14)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Unknown</td><td align="center" rowspan="1" colspan="1">1416 (9.29)</td><td align="center" rowspan="1" colspan="1">1013 (9.68)</td><td align="center" rowspan="1" colspan="1">403 (8.14)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>ACE, angiotensin converting enzyme; ALP, alkaline phosphatase; CRP, C-reactive protein; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; GED, General Educational Development; LYM%, lymphocyte percentage; MCV, mean cell volume; MET, metabolic equivalent; PA, physical activity; PIR, income-to-poverty ratio; RDW, red blood cell distribution width; <italic toggle="yes">t</italic>, weighted t test; WBC, white blood cell; <italic toggle="yes">r</italic>&#178;, Rao&#8211;Scott Chi-square test.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>The outcome information of participants</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Total (<italic toggle="yes">n</italic>&#8197;=&#8197;14 352)</th><th align="center" rowspan="1" colspan="1">Survival group (<italic toggle="yes">n</italic>&#8197;=&#8197;9735)</th><th align="center" rowspan="1" colspan="1">Death group (<italic toggle="yes">n</italic>&#8197;=&#8197;4617)</th><th align="center" rowspan="1" colspan="1">Statistics</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">Status CVD, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">&#967;</italic>&#178; = 6411.785</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Survival</td><td align="center" rowspan="1" colspan="1">9735 (75.12)</td><td align="center" rowspan="1" colspan="1">9735 (100.00)</td><td align="center" rowspan="1" colspan="1">0 (0.00)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Died of CVD</td><td align="center" rowspan="1" colspan="1">1555 (8.04)</td><td align="center" rowspan="1" colspan="1">0 (0.00)</td><td align="center" rowspan="1" colspan="1">1555 (32.33)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Died of other reasons</td><td align="center" rowspan="1" colspan="1">3062 (16.84)</td><td align="center" rowspan="1" colspan="1">0 (0.00)</td><td align="center" rowspan="1" colspan="1">3062 (67.67)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>CVD, cardiovascular disease; <italic toggle="yes">&#967;</italic>&#178;, Rao&#8211;Scott Chi-square test.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="F2" orientation="portrait"><label>Fig. 2</label><caption><p>The box plot showing the median levels of phenotypic age in participants in the alive group and the death group.</p></caption><graphic position="float" orientation="portrait" xlink:href="bpmj-30-222-g002.jpg"/></fig><fig position="float" id="F3" orientation="portrait"><label>Fig. 3</label><caption><p>The box plot showing the median levels of phenotypic age acceleration in the alive group and the death group.</p></caption><graphic position="float" orientation="portrait" xlink:href="bpmj-30-222-g003.jpg"/></fig><fig position="float" id="F4" orientation="portrait"><label>Fig. 4</label><caption><p>The box plot of the median levels of phenotypic age in participants in the non-CVD death group and the CVD death group. CVD, cardiovascular disease.</p></caption><graphic position="float" orientation="portrait" xlink:href="bpmj-30-222-g004.jpg"/></fig><fig position="float" id="F5" orientation="portrait"><label>Fig. 5</label><caption><p>The box plot of the median levels of phenotypic age acceleration in the non-CVD death group and the CVD death group. CVD, cardiovascular disease.</p></caption><graphic position="float" orientation="portrait" xlink:href="bpmj-30-222-g005.jpg"/></fig></sec><sec sec-type="subjects"><title>Association between phenotypic age/phenotypic age acceleration and all-cause mortality in hypertensive patients</title><p>Race, PIR, marital status, education, BMI, physical activity, drinking, smoking, carbohydrate, eGFR, diabetes, dyslipidemia, CVD, cancer, arthritis, and medication for hypertension were confounding factors associated with all-cause mortality in hypertensive patients (Table <xref rid="T3" ref-type="table">3</xref>). In the crude model, patients with PhenoAge of T1&#8211;T2 group (hazard ratio&#8197;=&#8197;5.05, 95% CI: 4.42&#8211;5.77, <italic toggle="yes">P</italic>&#8197;&lt;&#8197;0.001) and greater than or equal to T2 group (hazard ratio&#8197;=&#8197;23.58, 95% CI: 20.72&#8211;26.83, <italic toggle="yes">P</italic>&#8197;&lt;&#8197;0.001) were correlated with elevated all-cause mortality. After controlling for potential confounders, increased all-cause mortality was observed in hypertensive patients with PhenoAge of T1&#8211;T2 group (hazard ratio&#8197;=&#8197;4.21, 95% CI: 3.62&#8211;4.89, <italic toggle="yes">P</italic>&#8197;&lt;&#8197;0.001) and greater than or equal to T2 (hazard ratio&#8197;=&#8197;13.50, 95% CI: 11.62&#8211;15.69, <italic toggle="yes">P</italic>&#8197;&lt;&#8197;0.001). PhenoAgeAccel of T1&#8211;T2 (hazard ratio&#8197;=&#8197;1.17, 95% CI: 1.04&#8211;1.31, <italic toggle="yes">P</italic>&#8197;&lt;&#8197;0.001) and PhenoAgeAccel greater than or equal to T2 (hazard ratio&#8197;=&#8197;2.28, 95% CI: 2.08&#8211;2.50, <italic toggle="yes">P</italic>&#8197;&lt;&#8197;0.001) was related to increased risk of all-cause mortality in hypertensive patients in the unadjusted model. Significant association between PhenoAgeAccel greater than or equal to T2 and increased risk of all-cause mortality in hypertensive patients was observed after adjusting the confounding factors (hazard ratio&#8197;=&#8197;1.38, 95% CI: 1.26&#8211;1.52, <italic toggle="yes">P</italic>&#8197;&lt;&#8197;0.001) (Table <xref rid="T4" ref-type="table">4</xref>).</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><p>Potential confounding factors associated with all-cause mortality of hypertensive patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="3" rowspan="1">Gender</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Female</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Male</td><td align="center" rowspan="1" colspan="1">0.98 (0.91&#8211;1.04)</td><td align="center" rowspan="1" colspan="1">0.453</td></tr><tr><td align="left" colspan="3" rowspan="1">Race</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Non-Hispanic White</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Non-Hispanic Black</td><td align="center" rowspan="1" colspan="1">0.81 (0.74&#8211;0.88)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Mexican American</td><td align="center" rowspan="1" colspan="1">0.49 (0.41&#8211;0.58)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Other race</td><td align="center" rowspan="1" colspan="1">0.58 (0.48&#8211;0.71)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="3" rowspan="1">PIR</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;1</td><td align="center" rowspan="1" colspan="1">0.81 (0.72&#8211;0.90)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Unknown</td><td align="center" rowspan="1" colspan="1">1.04 (0.87&#8211;1.25)</td><td align="center" rowspan="1" colspan="1">0.645</td></tr><tr><td align="left" colspan="3" rowspan="1">Marriage</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Married/living with partner</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Widowed/divorced/separated/never married</td><td align="center" rowspan="1" colspan="1">1.65 (1.52&#8211;1.78)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="3" rowspan="1">Education</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Below high school</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;High school/GED or equivalent</td><td align="center" rowspan="1" colspan="1">0.61 (0.55&#8211;0.67)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Above high school</td><td align="center" rowspan="1" colspan="1">0.44 (0.40&#8211;0.48)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="3" rowspan="1">BMI</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;25</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;25&#8211;30</td><td align="center" rowspan="1" colspan="1">0.80 (0.72&#8211;0.89)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;30</td><td align="center" rowspan="1" colspan="1">0.69 (0.63&#8211;0.75)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="3" rowspan="1">PA</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;600</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;600</td><td align="center" rowspan="1" colspan="1">0.67 (0.60&#8211;0.74)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Unknown</td><td align="center" rowspan="1" colspan="1">1.37 (1.25&#8211;1.50)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="3" rowspan="1">Drinking</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">0.56 (0.51&#8211;0.62)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Unknown</td><td align="center" rowspan="1" colspan="1">1.28 (1.16&#8211;1.42)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="3" rowspan="1">Smoking</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">1.54 (1.45&#8211;1.64)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Protein</td><td align="center" rowspan="1" colspan="1">1.00 (1.00&#8211;1.01)</td><td align="center" rowspan="1" colspan="1">0.316</td></tr><tr><td align="left" rowspan="1" colspan="1">Carbohydrate</td><td align="center" rowspan="1" colspan="1">1.01 (1.00&#8211;1.01)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Total fat</td><td align="center" rowspan="1" colspan="1">1.00 (1.00&#8211;1.00)</td><td align="center" rowspan="1" colspan="1">0.722</td></tr><tr><td align="left" colspan="3" rowspan="1">eGFR</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;60</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;60</td><td align="center" rowspan="1" colspan="1">0.17 (0.15&#8211;0.18)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="3" rowspan="1">Diabetes</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">2.44 (2.26&#8211;2.63)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="3" rowspan="1">Dyslipidemia</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">1.35 (1.23&#8211;1.49)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="3" rowspan="1">CVD</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">4.04 (3.72&#8211;4.38)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="3" rowspan="1">Cancer</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">2.61 (2.38&#8211;2.86)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="3" rowspan="1">Arthritis</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">2.36 (2.19&#8211;2.53)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="3" rowspan="1">Medication for hypertension</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No use</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Only one type</td><td align="center" rowspan="1" colspan="1">2.57 (2.30&#8211;2.88)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;2 types</td><td align="center" rowspan="1" colspan="1">3.69 (3.34&#8211;4.08)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Unknown</td><td align="center" rowspan="1" colspan="1">1.69 (1.42&#8211;2.01)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>CI, confidence interval; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; GED, General Educational Development; HR, hazard ratio; PA, physical activity; PIR, income-to-poverty ratio.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T4" orientation="portrait"><label>Table 4</label><caption><p>Association between phenotypic age acceleration/phenotypic age acceleration and all-cause mortality in hypertensive patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Variables</th><th align="center" colspan="2" rowspan="1">Model 1</th><th align="center" colspan="2" rowspan="1">Model 2</th></tr><tr><th align="left" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th><th align="center" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">Phenotypic age</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">5.05 (4.42&#8211;5.77)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">4.21 (3.62&#8211;4.89)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">23.58 (20.72&#8211;26.83)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">13.50 (11.62&#8211;15.69)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Phenotypic age acceleration</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">1.17 (1.04&#8211;1.31)</td><td align="center" rowspan="1" colspan="1">0.008</td><td align="center" rowspan="1" colspan="1">1.08 (0.95&#8211;1.21)</td><td align="center" rowspan="1" colspan="1">0.238</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">2.28 (2.08&#8211;2.50)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">1.38 (1.26&#8211;1.52)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>CI, confidence interval; HR, hazard ratio.</p></fn><fn fn-type="other"><p>Model 1: the crude model. Model 2: adjusted for race, income-to-poverty ratio, marital status, education, BMI, physical activity, drinking, smoking, carbohydrate, estimated glomerular filtration rate, diabetes, dyslipidemia, cardiovascular disease, cancer, arthritis, and medication for hypertension.</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="subjects"><title>Association between phenotypic age/phenotypic age acceleration and cardiovascular disease&#8211;related mortality in hypertensive patients</title><p>As exhibited in Table <xref rid="T5" ref-type="table">5</xref>, race, marital status, education, BMI, physical activity, drinking, smoking, carbohydrate, eGFR, diabetes, dyslipidemia, CVD, cancer, arthritis, and medication for hypertension were confounders correlated with CVD-related mortality in hypertensive patients. PhenoAge of T1&#8211;T2 (hazard ratio&#8197;=&#8197;6.29, 95% CI: 4.77&#8211;8.29, <italic toggle="yes">P</italic>&#8197;&lt;&#8197;0.001) and greater than or equal to T2 (hazard ratio&#8197;=&#8197;37.72, 95% CI: 29.83&#8211;47.70, <italic toggle="yes">P</italic>&#8197;&lt;&#8197;0.001) was associated with elevated risk of CVD-related mortality in hypertensive patients who were in the unadjusted model. In the fully adjusted model, we found that PhenoAge of T1&#8211;T2 and greater than or equal to T2 were related to increased CVD-related mortality in hypertensive patients, respectively hazard ratio&#8197;=&#8197;4.58, 95% CI: 3.40&#8211;6.17, <italic toggle="yes">P</italic>&#8197;&lt;&#8197;0.001 and hazard ratio&#8197;=&#8197;17.52, 95% CI: 12.76&#8211;24.06, <italic toggle="yes">P</italic>&#8197;&lt;&#8197;0.001. Also, in the adjusted model, increased risk of CVD-related mortality was identified in hypertensive patients with PhenoAgeAccel greater than or equal to T2 (hazard ratio&#8197;=&#8197;1.29, 95% CI: 1.11&#8211;1.50, <italic toggle="yes">P</italic>&#8197;&lt;&#8197;0.001) (Table <xref rid="T6" ref-type="table">6</xref>).</p><table-wrap position="float" id="T5" orientation="portrait"><label>Table 5</label><caption><p>Potential confounding factors associated with cardiovascular disease&#8211;related mortality of hypertensive patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="3" rowspan="1">Gender</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Female</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Male</td><td align="center" rowspan="1" colspan="1">0.98 (0.88&#8211;1.10)</td><td align="center" rowspan="1" colspan="1">0.758</td></tr><tr><td align="left" colspan="3" rowspan="1">Race</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Non-Hispanic White</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Non-Hispanic Black</td><td align="center" rowspan="1" colspan="1">0.83 (0.72&#8211;0.95)</td><td align="center" rowspan="1" colspan="1">0.007</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Mexican American</td><td align="center" rowspan="1" colspan="1">0.40 (0.30&#8211;0.53)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Other race</td><td align="center" rowspan="1" colspan="1">0.52 (0.40&#8211;0.68)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="3" rowspan="1">PIR</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;1</td><td align="center" rowspan="1" colspan="1">0.87 (0.73&#8211;1.03)</td><td align="center" rowspan="1" colspan="1">0.115</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Unknown</td><td align="center" rowspan="1" colspan="1">1.04 (0.80&#8211;1.33)</td><td align="center" rowspan="1" colspan="1">0.788</td></tr><tr><td align="left" rowspan="1" colspan="1">Marriage</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Married/living with partner</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Widowed/divorced/separated/never married</td><td align="center" rowspan="1" colspan="1">1.79 (1.55&#8211;2.08)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="3" rowspan="1">Education</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Below high school</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;High school/GED or equivalent</td><td align="center" rowspan="1" colspan="1">0.53 (0.43&#8211;0.65)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Above high school</td><td align="center" rowspan="1" colspan="1">0.41 (0.35&#8211;0.48)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="3" rowspan="1">BMI</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;25</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;25&#8211;30</td><td align="center" rowspan="1" colspan="1">0.85 (0.71&#8211;1.01)</td><td align="center" rowspan="1" colspan="1">0.068</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;30</td><td align="center" rowspan="1" colspan="1">0.77 (0.67&#8211;0.90)</td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" colspan="3" rowspan="1">PA</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;600</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;600</td><td align="center" rowspan="1" colspan="1">0.70 (0.59&#8211;0.82)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Unknown</td><td align="center" rowspan="1" colspan="1">1.59 (1.38&#8211;1.84)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="3" rowspan="1">Drinking</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">0.48 (0.42&#8211;0.55)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Unknown</td><td align="center" rowspan="1" colspan="1">1.09 (0.94&#8211;1.27)</td><td align="center" rowspan="1" colspan="1">0.256</td></tr><tr><td align="left" colspan="3" rowspan="1">Smoking</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">1.30 (1.17&#8211;1.44)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Protein</td><td align="center" rowspan="1" colspan="1">1.01 (1.00&#8211;1.02)</td><td align="center" rowspan="1" colspan="1">0.084</td></tr><tr><td align="left" rowspan="1" colspan="1">Carbohydrate</td><td align="center" rowspan="1" colspan="1">1.01 (1.00&#8211;1.01)</td><td align="center" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1">Total fat</td><td align="center" rowspan="1" colspan="1">1.00 (1.00&#8211;1.01)</td><td align="center" rowspan="1" colspan="1">0.730</td></tr><tr><td align="left" colspan="3" rowspan="1">eGFR</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;60</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;60</td><td align="center" rowspan="1" colspan="1">0.14 (0.12&#8211;0.16)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="3" rowspan="1">Diabetes</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">2.83 (2.46&#8211;3.26)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="3" rowspan="1">Dyslipidemia</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">1.60 (1.32&#8211;1.93)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">CVD</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">5.93 (5.23&#8211;6.71)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Cancer</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">2.20 (1.86&#8211;2.60)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Arthritis</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">2.55 (2.28&#8211;2.85)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Medication for hypertension</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No use</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Only one type</td><td align="center" rowspan="1" colspan="1">3.36 (2.83&#8211;3.99)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;2 Types</td><td align="center" rowspan="1" colspan="1">6.28 (5.36&#8211;7.35)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Unknown</td><td align="center" rowspan="1" colspan="1">2.01 (1.53&#8211;2.64)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>CI, confidence intervals; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; GED, General Educational Development; HR, hazard ratio; PA, physical activity; PIR, income-to-poverty ratio.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T6" orientation="portrait"><label>Table 6</label><caption><p>Relationship of phenotypic age/phenotypic age acceleration with cardiovascular disease&#8211;related mortality in hypertensive patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Variables</th><th align="center" colspan="2" rowspan="1">Model 1</th><th align="center" colspan="2" rowspan="1">Model 2</th></tr><tr><th align="left" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th><th align="center" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">Phenotypic age</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">6.29 (4.77&#8211;8.29)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">4.58 (3.40&#8211;6.17)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">37.72 (29.83&#8211;47.70)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">17.52 (12.76&#8211;24.06)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Phenotypic age acceleration</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">1.24 (1.07&#8211;1.43)</td><td align="center" rowspan="1" colspan="1">0.003</td><td align="center" rowspan="1" colspan="1">1.07 (0.92&#8211;1.24)</td><td align="center" rowspan="1" colspan="1">0.361</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">2.48 (2.16&#8211;2.86)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">1.29 (1.11&#8211;1.50)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>CI, confidence interval; HR, hazard ratio.</p></fn><fn fn-type="other"><p>Model 1: the crude model. Model 2: adjusted for race, marital status, education, BMI, physical activity, drinking, smoking, carbohydrate, estimated glomerular filtration rate, diabetes, dyslipidemia, cardiovascular disease, cancer, arthritis, and medication for hypertension.</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="subjects"><title>Subgroup analysis on the associations of phenotypic age with all-cause mortality and cardiovascular disease&#8211;related mortality in hypertensive patients</title><p>PhenoAge of T1&#8211;T2 and greater than or equal to T2 were correlated with increased all-cause mortality in both male and female hypertensive patients. PhenoAge of T1&#8211;T2 and greater than or equal to T2 were correlated with increased all-cause mortality in hypertensive patients with different BMIs. No matter patients complicated with diabetes, dyslipidemia, CVD, cancer, arthritis, or not, PhenoAge of T1&#8211;T2 and greater than or equal to T2 were correlated with increased all-cause mortality. In hypertensive male or female patients, PhenoAge of T1&#8211;T2 and greater than or equal to T2 were associated with CVD-related mortality. In patients with different BMIs, PhenoAge of T1&#8211;T2 and greater than or equal to T2 were associated with CVD-related mortality. In both patients complicated with dyslipidemia, CVD, cancer, arthritis, or not, PhenoAge of T1&#8211;T2 and greater than or equal to T2 were associated with CVD-related mortality. In hypertensive patients complicated with diabetes, the odds ratio of CVD-related mortality was increased in PhenoAge greater than or equal to T2 (Table <xref rid="T7" ref-type="table">7</xref>).</p><table-wrap position="float" id="T7" orientation="portrait"><label>Table 7</label><caption><p>Subgroup analysis on the associations of phenotypic age with all-cause mortality and cardiovascular disease&#8211;related mortality in hypertensive patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Subgroups</th><th align="center" colspan="2" rowspan="1">All-cause mortality</th><th align="center" colspan="2" rowspan="1">CVD-related mortality</th></tr><tr><th align="left" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th><th align="center" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">Gender: female</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">4.32 (3.31&#8211;5.64)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">5.14 (3.00&#8211;8.79)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">14.47 (11.28&#8211;18.56)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">22.28 (13.74&#8211;36.12)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Gender: male</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">4.31 (3.44&#8211;5.40)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">4.46 (3.17&#8211;6.28)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">12.85 (10.20&#8211;16.20)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">14.51 (9.38&#8211;22.44)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">BMI&#8197;&lt;&#8197;25</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">5.36 (3.85&#8211;7.45)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">5.25 (2.79&#8211;9.88)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">19.61 (14.32&#8211;26.86)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">22.45 (10.15&#8211;49.63)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">BMI: 25&#8211;30</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">3.96 (3.06&#8211;5.13)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">3.46 (2.22&#8211;5.40)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">13.18 (9.96&#8211;17.44)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">15.42 (10.42&#8211;22.82)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">BMI&#8197;&#8805;&#8197;30</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">3.72 (2.90&#8211;4.77)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">5.36 (3.10&#8211;9.28)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">10.76 (8.29&#8211;13.96)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">17.14 (10.11&#8211;29.06)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Diabetes: no</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">4.48 (3.73&#8211;5.39)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">5.22 (3.64&#8211;7.49)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">16.05 (13.29&#8211;19.38)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">23.91 (16.23&#8211;35.22)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Diabetes: yes</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">1.73 (1.14&#8211;2.63)</td><td align="center" rowspan="1" colspan="1">0.010</td><td align="center" rowspan="1" colspan="1">1.48 (0.70&#8211;3.09)</td><td align="center" rowspan="1" colspan="1">0.298</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">4.48 (2.93&#8211;6.84)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">3.91 (1.98&#8211;7.71)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Dyslipidemia: no</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">4.69 (3.10&#8211;7.10)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">4.37 (2.15&#8211;8.88)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">15.47 (10.30&#8211;23.22)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">21.72 (9.66&#8211;48.83)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Dyslipidemia: yes</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">4.05 (3.35&#8211;4.90)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">4.57 (2.99&#8211;6.99)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">12.89 (10.89&#8211;15.26)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">16.84 (11.29&#8211;25.14)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">CVD: no</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">4.31 (3.67&#8211;5.06)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">4.88 (3.52&#8211;6.77)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">14.78 (12.52&#8211;17.44)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">20.77 (14.34&#8211;30.09)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">CVD: yes</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">2.95 (1.90&#8211;4.60)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">2.58 (1.15&#8211;5.77)</td><td align="center" rowspan="1" colspan="1">0.021</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">7.77 (5.02&#8211;12.03)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">7.74 (3.69&#8211;16.24)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Cancer: no</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">4.15 (3.56&#8211;4.83)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">4.56 (3.35&#8211;6.21)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">13.41 (11.41&#8211;15.76)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">16.94 (12.04&#8211;23.83)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Cancer: yes</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">4.14 (1.96&#8211;8.71)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">6.22 (1.63&#8211;23.79)</td><td align="center" rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">12.61 (6.18&#8211;25.73)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">28.02 (6.49&#8211;121.01)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Arthritis: no</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">4.15 (3.42&#8211;5.04)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">5.05 (3.37&#8211;7.56)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">14.58 (12.07&#8211;17.62)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">22.48 (14.42&#8211;35.06)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Arthritis: yes</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">3.63 (2.66&#8211;4.94)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">2.98 (1.57&#8211;5.65)</td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">10.80 (7.81&#8211;14.93)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">10.13 (5.41&#8211;18.97)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio.</p></fn><fn fn-type="other"><p>If not stratified, race, income-to-poverty ratio, marital status, education, BMI, physical activity, drinking, smoking, carbohydrate, estimated glomerular filtration rate, diabetes, dyslipidemia, cardiovascular disease, cancer, arthritis, and medication for hypertension were adjusted in the all-cause mortality model.</p></fn><fn fn-type="other"><p>If not stratified, race, marital status, education, BMI, physical activity, drinking, smoking, carbohydrate, estimated glomerular filtration rate, diabetes, dyslipidemia, cardiovascular disease, cancer, arthritis, and medication for hypertension were adjusted in the cardiovascular disease&#8211;related mortality model.</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="subjects"><title>Subgroup analysis on the associations of phenotypic age acceleration with all-cause mortality and cardiovascular disease&#8211;related mortality in hypertensive patients</title><p>PhenoAgeAccel greater than or equal to T2 was related to elevated risk of all-cause mortality in female hypertensive patients. PhenoAgeAccel greater than or equal to T2 was related to elevated risk of all-cause mortality in hypertensive patients without cancer or arthritis. PhenoAgeAccel of T1&#8211;T2 and greater than or equal to T2 were associated with heightened all-cause mortality risk in males, or patients complicated with cancer or arthritis. Regardless of BMI, increased risk of all-cause mortality was observed in PhenoAgeAccel greater than or equal to the T2 group. In both patients with or without diabetes, dyslipidemia, or CVD, increased risk of all-cause mortality was observed in PhenoAgeAccel greater than or equal to the T2 group. In patients with a BMI less than 25&#8197;kg/m<sup>2</sup>, or patients without diabetes, PhenoAgeAccel of greater than or equal to T2 was associated with elevated CVD-related mortality (Table <xref rid="T8" ref-type="table">8</xref>).</p><table-wrap position="float" id="T8" orientation="portrait"><label>Table 8</label><caption><p>Subgroup analysis on the associations of phenotypic age acceleration with all-cause mortality and cardiovascular disease&#8211;related mortality in hypertensive patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Subgroups</th><th align="center" colspan="2" rowspan="1">All-cause mortality</th><th align="center" colspan="2" rowspan="1">CVD-related mortality</th></tr><tr><th align="left" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th><th align="center" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">Gender: female</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">0.96 (0.82&#8211;1.13)</td><td align="center" rowspan="1" colspan="1">0.627</td><td align="center" rowspan="1" colspan="1">1.04 (0.82&#8211;1.31)</td><td align="center" rowspan="1" colspan="1">0.755</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">1.23 (1.06&#8211;1.41)</td><td align="center" rowspan="1" colspan="1">0.005</td><td align="center" rowspan="1" colspan="1">1.29 (1.02&#8211;1.62)</td><td align="center" rowspan="1" colspan="1">0.032</td></tr><tr><td align="left" colspan="5" rowspan="1">Gender: male</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">1.22 (1.02&#8211;1.46)</td><td align="center" rowspan="1" colspan="1">0.026</td><td align="center" rowspan="1" colspan="1">1.05 (0.82&#8211;1.35)</td><td align="center" rowspan="1" colspan="1">0.676</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">1.56 (1.30&#8211;1.87)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">1.21 (0.95&#8211;1.54)</td><td align="center" rowspan="1" colspan="1">0.127</td></tr><tr><td align="left" colspan="5" rowspan="1">BMI&#8197;&lt;&#8197;25</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">1.11 (0.93&#8211;1.32)</td><td align="center" rowspan="1" colspan="1">0.248</td><td align="center" rowspan="1" colspan="1">1.25 (0.95&#8211;1.64)</td><td align="center" rowspan="1" colspan="1">0.107</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">1.56 (1.31&#8211;1.86)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">1.45 (1.08&#8211;1.96)</td><td align="center" rowspan="1" colspan="1">0.015</td></tr><tr><td align="left" colspan="5" rowspan="1">BMI: 25&#8211;30</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">1.05 (0.92&#8211;1.21)</td><td align="center" rowspan="1" colspan="1">0.462</td><td align="center" rowspan="1" colspan="1">1.02 (0.82&#8211;1.27)</td><td align="center" rowspan="1" colspan="1">0.878</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">1.39 (1.17&#8211;1.64)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">1.28 (1.02&#8211;1.60)</td><td align="center" rowspan="1" colspan="1">0.032</td></tr><tr><td align="left" colspan="5" rowspan="1">BMI&#8197;&#8805;&#8197;30</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">1.09 (0.86&#8211;1.37)</td><td align="center" rowspan="1" colspan="1">0.470</td><td align="center" rowspan="1" colspan="1">0.97 (0.67&#8211;1.41)</td><td align="center" rowspan="1" colspan="1">0.869</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">1.34 (1.08&#8211;1.66)</td><td align="center" rowspan="1" colspan="1">0.008</td><td align="center" rowspan="1" colspan="1">1.21 (0.87&#8211;1.68)</td><td align="center" rowspan="1" colspan="1">0.259</td></tr><tr><td align="left" colspan="5" rowspan="1">Diabetes: no</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">1.08 (0.95&#8211;1.24)</td><td align="center" rowspan="1" colspan="1">0.234</td><td align="center" rowspan="1" colspan="1">1.13 (0.97&#8211;1.33)</td><td align="center" rowspan="1" colspan="1">0.120</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">1.39 (1.24&#8211;1.55)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">1.41 (1.17&#8211;1.70)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Diabetes: yes</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">0.96 (0.73&#8211;1.26)</td><td align="center" rowspan="1" colspan="1">0.771</td><td align="center" rowspan="1" colspan="1">0.75 (0.48&#8211;1.19)</td><td align="center" rowspan="1" colspan="1">0.219</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">1.25 (1.01&#8211;1.54)</td><td align="center" rowspan="1" colspan="1">0.044</td><td align="center" rowspan="1" colspan="1">0.91 (0.66&#8211;1.24)</td><td align="center" rowspan="1" colspan="1">0.537</td></tr><tr><td align="left" colspan="5" rowspan="1">Dyslipidemia: no</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">1.02 (0.81&#8211;1.29)</td><td align="center" rowspan="1" colspan="1">0.884</td><td align="center" rowspan="1" colspan="1">1.15 (0.73&#8211;1.82)</td><td align="center" rowspan="1" colspan="1">0.537</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">1.35 (1.03&#8211;1.76)</td><td align="center" rowspan="1" colspan="1">0.031</td><td align="center" rowspan="1" colspan="1">1.48 (0.93&#8211;2.37)</td><td align="center" rowspan="1" colspan="1">0.099</td></tr><tr><td align="left" colspan="5" rowspan="1">Dyslipidemia: yes</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">1.09 (0.95&#8211;1.24)</td><td align="center" rowspan="1" colspan="1">0.205</td><td align="center" rowspan="1" colspan="1">1.06 (0.89&#8211;1.26)</td><td align="center" rowspan="1" colspan="1">0.523</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">1.40 (1.25&#8211;1.56)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">1.27 (1.08&#8211;1.49)</td><td align="center" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" colspan="5" rowspan="1">CVD: no</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">1.09 (0.95&#8211;1.25)</td><td align="center" rowspan="1" colspan="1">0.232</td><td align="center" rowspan="1" colspan="1">1.24 (1.01&#8211;1.52)</td><td align="center" rowspan="1" colspan="1">0.045</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">1.41 (1.26&#8211;1.58)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">1.37 (1.12&#8211;1.68)</td><td align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" colspan="5" rowspan="1">CVD: yes</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">0.99 (0.84&#8211;1.19)</td><td align="center" rowspan="1" colspan="1">0.993</td><td align="center" rowspan="1" colspan="1">0.81 (0.64&#8211;1.03)</td><td align="center" rowspan="1" colspan="1">0.088</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">1.31 (1.09&#8211;1.58)</td><td align="center" rowspan="1" colspan="1">0.005</td><td align="center" rowspan="1" colspan="1">1.13 (0.89&#8211;1.44)</td><td align="center" rowspan="1" colspan="1">0.310</td></tr><tr><td align="left" colspan="5" rowspan="1">Cancer: no</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">1.03 (0.90&#8211;1.17)</td><td align="center" rowspan="1" colspan="1">0.716</td><td align="center" rowspan="1" colspan="1">1.05 (0.90&#8211;1.22)</td><td align="center" rowspan="1" colspan="1">0.506</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">1.27 (1.12&#8211;1.43)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">1.26 (1.06&#8211;1.50)</td><td align="center" rowspan="1" colspan="1">0.010</td></tr><tr><td align="left" colspan="5" rowspan="1">Cancer: yes</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">1.31 (1.03&#8211;1.67)</td><td align="center" rowspan="1" colspan="1">0.028</td><td align="center" rowspan="1" colspan="1">1.16 (0.78&#8211;1.74)</td><td align="center" rowspan="1" colspan="1">0.460</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">2.08 (1.67&#8211;2.60)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">1.52 (0.99&#8211;2.35)</td><td align="center" rowspan="1" colspan="1">0.055</td></tr><tr><td align="left" colspan="5" rowspan="1">Arthritis: no</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">1.01 (0.86&#8211;1.19)</td><td align="center" rowspan="1" colspan="1">0.916</td><td align="center" rowspan="1" colspan="1">0.99 (0.77&#8211;1.27)</td><td align="center" rowspan="1" colspan="1">0.936</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">1.38 (1.16&#8211;1.63)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">1.22 (0.92&#8211;1.60)</td><td align="center" rowspan="1" colspan="1">0.161</td></tr><tr><td align="left" colspan="5" rowspan="1">Arthritis: yes</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;T1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1&#8211;T2</td><td align="center" rowspan="1" colspan="1">1.18 (1.01&#8211;1.38)</td><td align="center" rowspan="1" colspan="1">0.043</td><td align="center" rowspan="1" colspan="1">1.17 (0.89&#8211;1.54)</td><td align="center" rowspan="1" colspan="1">0.263</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;T2</td><td align="center" rowspan="1" colspan="1">1.44 (1.25&#8211;1.64)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">1.37 (1.07&#8211;1.76)</td><td align="center" rowspan="1" colspan="1">0.014</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio.</p></fn><fn fn-type="other"><p>If not stratified, race, income-to-poverty ratio, marital status, education, BMI, physical activity, drinking, smoking, carbohydrate, estimated glomerular filtration rate, diabetes, dyslipidemia, cardiovascular disease, cancer, arthritis, and medication for hypertension were adjusted in the all-cause mortality model.</p></fn><fn fn-type="other"><p>If not stratified, race, marital status, education, BMI, physical activity, drinking, smoking, carbohydrate, estimated glomerular filtration rate, diabetes, dyslipidemia, cardiovascular disease, cancer, arthritis, and medication for hypertension were adjusted in the cardiovascular disease&#8211;related mortality model.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>In the current study, the association between PhenoAge or PhenoAgeAccel and all-cause or CVD-related mortality in hypertensive patients was investigated, respectively. The results indicated that PhenoAge greater than or equal to T1 was related to increased risk of all-cause and CVD-related mortality. PhenoAgeAccel greater than or equal to T2 was associated with elevated risk of all-cause and CVD-related mortality. The finding might provide a reference for risk stratification and management of hypertensive patients.</p><p>PhenoAge is an epigenetic indicator closely associated with the aging process created based on data from the NHANES by utilizing a formula to calculate its value using ten selected variables, including chronological age [<xref rid="R17" ref-type="bibr">17</xref>]. This measure exhibits significantly enhanced predictive capabilities compared to previous measurements in various aging outcomes, encompassing all-cause mortality, cancer incidence, healthy lifespan, physical function, and Alzheimer&#8217;s disease [<xref rid="R18" ref-type="bibr">18</xref>]. PhenoAge has been identified to be significantly associated with mortality risk (independent of chronological age), such that a 1-year increase in PhenoAge is associated with a 4.5% increase in the risk of all-cause mortality [<xref rid="R18" ref-type="bibr">18</xref>]. Previous studies have demonstrated the potential utility of this novel biomarker in facilitating the identification of individuals at risk, evaluating intervention effectiveness, and advancing research on the underlying biological mechanisms of aging. Each 1-year increment in PhenoAge, after adjustment for chronological age, was associated with a 9% elevated risk of all-cause mortality [<xref rid="R16" ref-type="bibr">16</xref>]. PhenoAge has been reported to outperform chronological age as a more robust predictor of hospital mortality among critically ill patients, with individuals exhibiting a PhenoAge greater than their chronological age associated with a nearly twofold increase in mortality risk (hazard ratio: 1.997) [<xref rid="R19" ref-type="bibr">19</xref>]. PhenoAge exhibits a robust association with overall mortality in patients diagnosed with multivessel coronary artery disease, with each 10-year increase in PhenoAge associated with a 51% increased mortality risk [<xref rid="R20" ref-type="bibr">20</xref>]. PhenoAgeAccel refers to a numerical value that quantifies the degree of biological aging or rejuvenation in relation to an individual&#8217;s chronological age [<xref rid="R21" ref-type="bibr">21</xref>]. PhenoAgeAccel encompasses a multifaceted aging process that impacts various physiological systems through intricate biological mechanisms [<xref rid="R22" ref-type="bibr">22</xref>]. Li <italic toggle="yes">et al</italic>. [<xref rid="R23" ref-type="bibr">23</xref>] have delineated that accelerated aging partially mediates the associations between lifestyles and CVD, cancer, and mortality in the UK and US populations. The presence of adaptive metabolic and inflammatory responses, together with PhenoAgeAccel greater than 0, was linked to a substantially higher mortality risk [<xref rid="R24" ref-type="bibr">24</xref>]. This prior work significantly supports to the results in our study. We found that PhenoAge greater than or equal to 46.6792 years was associated with an increased risk of all-cause and CVD-related mortality in hypertensive patients. Older PhenAge was a risk factor for the prognosis of hypertensive patients. More importantly, elevated risk of all-cause and CVD-related mortality was observed in hypertensive patients with PhenoAgeAccel greater than or equal to 0.9896, indicating that PhenoAge older than chronological age was associated with increased risk of all-cause and CVD-related mortality.</p><p>Aging is characterized by an imbalance between sympathetic and parasympathetic outflow to cardiovascular effector organs. This autonomic imbalance leads to a decline in the functionality of the cardiac vagal baroreceptor reflex during aging, thereby allowing uncontrolled activation of the sympathetic nervous system. Consequently, this imbalance adversely affects resting SBP and increases its variability. The impaired baroreflex function can also contribute to the development of additional features such as insulin resistance and metabolic syndrome during aging, because of the overlapping autonomic pathways that regulate cardiovascular and metabolic functions [<xref rid="R25" ref-type="bibr">25</xref>]. Pathological characteristics of the heart and blood vessels can be attributed to mechanisms such as oxidative stress and inflammation [<xref rid="R26" ref-type="bibr">26</xref>]. Chronic inflammation is a key determinant for both the aging process and the initiation and progression of hypertension [<xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R28" ref-type="bibr">28</xref>]. Elevated levels of inflammatory markers, such as tumor necrosis factor, CRP, and interleukin-6, indicate the activation of inflammaging [<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R29" ref-type="bibr">29</xref>], which is widely considered to be associated with a heightened susceptibility to frailty, biological aging, CVDs, multimorbidity, and premature mortality [<xref rid="R30" ref-type="bibr">30</xref>]. These factors may underlie the associations between PhenoAge/PhenoAgeAccel and the prognosis of hypertensive patients.</p><p>There were some strengths in our study. First, the data were from the NHANES database, which provides a large and demographically representative sample. Second, PhenoAge and PhenoAgeAccel were calculated based on routine laboratory indexes, which were easy to obtain and might help improve the clinical management of hypertension patients. The advancements in medical science have significantly extended the lifespan of individuals suffering from severe chronic illnesses, and the next clinical endeavor might be the enhancement of health span by mitigating biological aging [<xref rid="R31" ref-type="bibr">31</xref>]. The first limitation was that the data during the follow-up time were not available in the database, which might be some bias. Second, the study population was limited to Americans; the applicability of the results to other populations requires cautious interpretation.</p><sec><title>Conclusion</title><p>The current study explored the associations between PhenoAge/PhenoAgeAccel and all-cause as well as CVD-related mortality among hypertensive patients. Our results demonstrated that elevated PhenoAge or higher PhenoAgeAccel were independently associated with increased risks of both all-cause and CVD-related mortality. These findings could provide critical evidence for refining risk stratification and optimizing management strategies in hypertensive patients.</p></sec></sec><sec><title>Acknowledgements</title><p>This study was supported by Key Discipline Construction Project for Talent Cultivation &#8216;Traditional Chinese Medicine Cardiology&#8217; of National Administration of Traditional Chinese Medicine [No. 85 (2023)], Key Research Laboratory Construction Project of National Administration of Traditional Chinese Medicine (Lingnan TCM Academic School Inheritance) (No. 27 (2012), and Project of Traditional Chinese Medicine Bureau of Guangdong Province (No. 20215004).</p><sec sec-type="COI-statement"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><fig id="s001" position="anchor" orientation="portrait"><media xlink:href="bpmj-30-222-s001.docx" position="float" orientation="portrait"/></fig></sec></body><back><fn-group><fn fn-type="supplementary-material"><p>Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal&#8217;s website, <ext-link xlink:href="www.bpmonitoring.com" ext-link-type="uri">www.bpmonitoring.com</ext-link>.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><collab>NCD Risk Factor Collaboration (NCD-RisC)</collab>. <article-title>Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.</article-title><source>Lancet</source>. <year>2021</year>; <volume>398</volume>:<fpage>957</fpage>&#8211;<lpage>980</lpage>.<pub-id pub-id-type="pmid">34450083</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)01330-1</pub-id><pub-id pub-id-type="pmcid">PMC8446938</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aune</surname><given-names>D</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W</given-names></name><name name-style="western"><surname>Nie</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name></person-group>. <article-title>Hypertension and the risk of all-cause and cause-specific mortality: an outcome-wide association study of 67 causes of death in the National Health Interview Survey.</article-title><source>Biomed Res Int</source>. <year>2021</year>; <volume>2021</volume>:<fpage>9376134</fpage>.<pub-id pub-id-type="pmid">34337061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2021/9376134</pub-id><pub-id pub-id-type="pmcid">PMC8292050</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Meng</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name></person-group>. <article-title>Role of inflammation, immunity, and oxidative stress in hypertension: new insights and potential therapeutic targets.</article-title><source>Front Immunol</source>. <year>2022</year>; <volume>13</volume>:<fpage>1098725</fpage>.<pub-id pub-id-type="pmid">36703963</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.1098725</pub-id><pub-id pub-id-type="pmcid">PMC9871625</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Hu</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Mediating effect of successful aging on the relationship between psychological resilience and death anxiety among middle-aged and older adults with hypertension.</article-title><source>Front Public Health</source>. <year>2023</year>; <volume>11</volume>:<fpage>1116263</fpage>.<pub-id pub-id-type="pmid">37808974</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpubh.2023.1116263</pub-id><pub-id pub-id-type="pmcid">PMC10552859</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Mao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Pan</surname><given-names>G</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Sung</surname><given-names>HJ</given-names></name></person-group>. <article-title>Hydrodynamic benefit of impulsive bursting in a self-propelled flexible plate.</article-title><source>Phys Fluids</source>. <year>2021</year>; <volume>33</volume>:<fpage>111904</fpage>.</mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castro-Porras</surname><given-names>LV</given-names></name><name name-style="western"><surname>Rojas-Mart&#237;nez</surname><given-names>R</given-names></name><name name-style="western"><surname>Aguilar-Salinas</surname><given-names>CA</given-names></name><name name-style="western"><surname>Bello-Chavolla</surname><given-names>OY</given-names></name><name name-style="western"><surname>Becerril-Gutierrez</surname><given-names>C</given-names></name><name name-style="western"><surname>Escamilla-Nu&#241;ez</surname><given-names>C</given-names></name></person-group>. <article-title>Trends and age-period-cohort effects on hypertension mortality rates from 1998 to 2018 in Mexico.</article-title><source>Sci Rep</source>. <year>2021</year>; <volume>11</volume>:<fpage>17553</fpage>.<pub-id pub-id-type="pmid">34475436</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-96175-0</pub-id><pub-id pub-id-type="pmcid">PMC8413460</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamczyk</surname><given-names>MR</given-names></name><name name-style="western"><surname>Nevado</surname><given-names>RM</given-names></name><name name-style="western"><surname>Barettino</surname><given-names>A</given-names></name><name name-style="western"><surname>Fuster</surname><given-names>V</given-names></name><name name-style="western"><surname>Andr&#233;s</surname><given-names>V</given-names></name></person-group>. <article-title>Biological versus chronological aging: JACC focus seminar.</article-title><source>J Am Coll Cardiol</source>. <year>2020</year>; <volume>75</volume>:<fpage>919</fpage>&#8211;<lpage>930</lpage>.<pub-id pub-id-type="pmid">32130928</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2019.11.062</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#243;pez-Ot&#237;n</surname><given-names>C</given-names></name><name name-style="western"><surname>Blasco</surname><given-names>MA</given-names></name><name name-style="western"><surname>Partridge</surname><given-names>L</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>M</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G</given-names></name></person-group>. <article-title>The hallmarks of aging.</article-title><source>Cell</source>. <year>2013</year>; <volume>153</volume>:<fpage>1194</fpage>&#8211;<lpage>1217</lpage>.<pub-id pub-id-type="pmid">23746838</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2013.05.039</pub-id><pub-id pub-id-type="pmcid">PMC3836174</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuo</surname><given-names>CL</given-names></name><name name-style="western"><surname>Pilling</surname><given-names>LC</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Atkins</surname><given-names>JL</given-names></name><name name-style="western"><surname>Levine</surname><given-names>ME</given-names></name></person-group>. <article-title>Genetic associations for two biological age measures point to distinct aging phenotypes.</article-title><source>Aging Cell</source>. <year>2021</year>; <volume>20</volume>:<fpage>e13376</fpage>.<pub-id pub-id-type="pmid">34038024</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acel.13376</pub-id><pub-id pub-id-type="pmcid">PMC8208797</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>PL</given-names></name><name name-style="western"><surname>Horvath</surname><given-names>S</given-names></name><name name-style="western"><surname>Crimmins</surname><given-names>E</given-names></name><name name-style="western"><surname>Ferrucci</surname><given-names>L</given-names></name><name name-style="western"><surname>Levine</surname><given-names>M</given-names></name></person-group>. <article-title>A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: a cohort study.</article-title><source>PLoS Med</source>. <year>2018</year>; <volume>15</volume>:<fpage>e1002718</fpage>.<pub-id pub-id-type="pmid">30596641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.1002718</pub-id><pub-id pub-id-type="pmcid">PMC6312200</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name></person-group>. <article-title>Association of phenotypic age acceleration with all-cause and cardiovascular disease-specific mortality in individuals with prediabetes and diabetes: results from the NHANES study.</article-title><source>J Endocrinol Invest</source>. <year>2023</year>; <volume>46</volume>:<fpage>1475</fpage>&#8211;<lpage>1481</lpage>.<pub-id pub-id-type="pmid">36534298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40618-022-01992-3</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kresovich</surname><given-names>JK</given-names></name><name name-style="western"><surname>Sandler</surname><given-names>DP</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>JA</given-names></name></person-group>. <article-title>Methylation-based biological age and hypertension prevalence and incidence.</article-title><source>Hypertension</source>. <year>2023</year>; <volume>80</volume>:<fpage>1213</fpage>&#8211;<lpage>1222</lpage>.<pub-id pub-id-type="pmid">36974720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/HYPERTENSIONAHA.122.20796</pub-id><pub-id pub-id-type="pmcid">PMC10192055</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nie</surname><given-names>J</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name></person-group>. <article-title>Higher HEI-2015 score is associated with reduced risk of depression: result from NHANES 2005-2016.</article-title><source>Nutrients</source>. <year>2021</year>; <volume>13</volume>:<fpage>348</fpage>.<pub-id pub-id-type="pmid">33503826</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nu13020348</pub-id><pub-id pub-id-type="pmcid">PMC7911826</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whelton</surname><given-names>PK</given-names></name><name name-style="western"><surname>Carey</surname><given-names>RM</given-names></name><name name-style="western"><surname>Aronow</surname><given-names>WS</given-names></name><name name-style="western"><surname>Casey</surname><given-names>DE</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Collins</surname><given-names>KJ</given-names></name><etal/></person-group>. <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines.</article-title><source>Circulation</source>. <year>2018</year>; <volume>138</volume>:<fpage>e426</fpage>&#8211;<lpage>e483</lpage>.<pub-id pub-id-type="pmid">30354655</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIR.0000000000000597</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levey</surname><given-names>AS</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>LA</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>CH</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>YL</given-names></name><name name-style="western"><surname>Castro</surname><given-names>AF</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Feldman</surname><given-names>HI</given-names></name><etal/></person-group>; <collab>CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)</collab>. <article-title>A new equation to estimate glomerular filtration rate.</article-title><source>Ann Intern Med</source>. <year>2009</year>; <volume>150</volume>:<fpage>604</fpage>&#8211;<lpage>612</lpage>.<pub-id pub-id-type="pmid">19414839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/0003-4819-150-9-200905050-00006</pub-id><pub-id pub-id-type="pmcid">PMC2763564</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>PL</given-names></name><name name-style="western"><surname>Horvath</surname><given-names>S</given-names></name><name name-style="western"><surname>Crimmins</surname><given-names>E</given-names></name><name name-style="western"><surname>Ferrucci</surname><given-names>L</given-names></name><name name-style="western"><surname>Levine</surname><given-names>M</given-names></name></person-group>. <article-title>Correction: a new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: a cohort study.</article-title><source>PLoS Med</source>. <year>2019</year>; <volume>16</volume>:<fpage>e1002760</fpage>.<pub-id pub-id-type="pmid">30802240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.1002760</pub-id><pub-id pub-id-type="pmcid">PMC6388911</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guo</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Association of physical activity with phenotypic age among populations with different breakfast habits.</article-title><source>Nutrients</source>. <year>2024</year>; <volume>16</volume>:<fpage>575</fpage>.<pub-id pub-id-type="pmid">38474704</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nu16050575</pub-id><pub-id pub-id-type="pmcid">PMC10934488</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levine</surname><given-names>ME</given-names></name><name name-style="western"><surname>Lu</surname><given-names>AT</given-names></name><name name-style="western"><surname>Quach</surname><given-names>A</given-names></name><name name-style="western"><surname>Chen</surname><given-names>BH</given-names></name><name name-style="western"><surname>Assimes</surname><given-names>TL</given-names></name><name name-style="western"><surname>Bandinelli</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>An epigenetic biomarker of aging for lifespan and healthspan.</article-title><source>Aging (Milano)</source>. <year>2018</year>; <volume>10</volume>:<fpage>573</fpage>&#8211;<lpage>591</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.101414</pub-id><pub-id pub-id-type="pmcid">PMC5940111</pub-id><pub-id pub-id-type="pmid">29676998</pub-id></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ho</surname><given-names>KM</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Johnstone</surname><given-names>M</given-names></name><name name-style="western"><surname>Edibam</surname><given-names>C</given-names></name></person-group>. <article-title>Biological age is superior to chronological age in predicting hospital mortality of the critically ill.</article-title><source>Intern Emerg Med</source>. <year>2023</year>; <volume>18</volume>:<fpage>2019</fpage>&#8211;<lpage>2028</lpage>.<pub-id pub-id-type="pmid">37635161</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11739-023-03397-3</pub-id><pub-id pub-id-type="pmcid">PMC10543822</pub-id></mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>BL</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Feng</surname><given-names>XX</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>Association between phenotypic age and mortality in patients with multivessel coronary artery disease.</article-title><source>Dis Markers</source>. <year>2022</year>; <volume>2022</volume>:<fpage>4524032</fpage>.<pub-id pub-id-type="pmid">35069932</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2022/4524032</pub-id><pub-id pub-id-type="pmcid">PMC8776473</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reeves</surname><given-names>J</given-names></name><name name-style="western"><surname>Kooner</surname><given-names>JS</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name></person-group>. <article-title>Accelerated ageing is associated with increased COVID-19 severity and differences across ethnic groups may exist.</article-title><source>Front Public Health</source>. <year>2022</year>; <volume>10</volume>:<fpage>1034227</fpage>.<pub-id pub-id-type="pmid">36582365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpubh.2022.1034227</pub-id><pub-id pub-id-type="pmcid">PMC9792858</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>M</given-names></name><name name-style="western"><surname>Fang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Song</surname><given-names>X</given-names></name><name name-style="western"><surname>Jin</surname><given-names>L</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name></person-group>. <article-title>Associations of sleeping, sedentary and physical activity with phenotypic age acceleration: a cross-sectional isotemporal substitution model.</article-title><source>BMC Geriatr</source>. <year>2023</year>; <volume>23</volume>:<fpage>165</fpage>.<pub-id pub-id-type="pmid">36959562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12877-023-03874-6</pub-id><pub-id pub-id-type="pmcid">PMC10035275</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Cao</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Fu</surname><given-names>J</given-names></name><name name-style="western"><surname>Mohedaner</surname><given-names>M</given-names></name></person-group>. <article-title>Accelerated aging mediates the associations of unhealthy lifestyles with cardiovascular disease, cancer, and mortality.</article-title><source>J Am Geriatr Soc</source>. <year>2024</year>; <volume>72</volume>:<fpage>181</fpage>&#8211;<lpage>193</lpage>.<pub-id pub-id-type="pmid">37789775</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jgs.18611</pub-id><pub-id pub-id-type="pmcid">PMC11078652</pub-id></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#225;rquez-Salinas</surname><given-names>A</given-names></name><name name-style="western"><surname>Ferm&#237;n-Mart&#237;nez</surname><given-names>CA</given-names></name><name name-style="western"><surname>Antonio-Villa</surname><given-names>NE</given-names></name><name name-style="western"><surname>Vargas-V&#225;zquez</surname><given-names>A</given-names></name><name name-style="western"><surname>Guerra</surname><given-names>EC</given-names></name><name name-style="western"><surname>Campos-Mu&#241;oz</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Adaptive metabolic and inflammatory responses identified using accelerated aging metrics are linked to adverse outcomes in severe SARS-CoV-2 infection.</article-title><source>J Gerontol A Biol Sci Med Sci</source>. <year>2021</year>; <volume>76</volume>:<fpage>e117</fpage>&#8211;<lpage>e126</lpage>.<pub-id pub-id-type="pmid">33721886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/gerona/glab078</pub-id><pub-id pub-id-type="pmcid">PMC7989655</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arnold</surname><given-names>AC</given-names></name><name name-style="western"><surname>Gallagher</surname><given-names>PE</given-names></name><name name-style="western"><surname>Diz</surname><given-names>DI</given-names></name></person-group>. <article-title>Brain renin-angiotensin system in the nexus of hypertension and aging.</article-title><source>Hypertens Res</source>. <year>2013</year>; <volume>36</volume>:<fpage>5</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">23076408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/hr.2012.161</pub-id><pub-id pub-id-type="pmcid">PMC3816955</pub-id></mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costantino</surname><given-names>S</given-names></name><name name-style="western"><surname>Paneni</surname><given-names>F</given-names></name><name name-style="western"><surname>Cosentino</surname><given-names>F</given-names></name></person-group>. <article-title>Ageing, metabolism and cardiovascular disease.</article-title><source>J Physiol</source>. <year>2016</year>; <volume>594</volume>:<fpage>2061</fpage>&#8211;<lpage>2073</lpage>.<pub-id pub-id-type="pmid">26391109</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1113/JP270538</pub-id><pub-id pub-id-type="pmcid">PMC4933114</pub-id></mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deussen</surname><given-names>A</given-names></name><name name-style="western"><surname>Kopaliani</surname><given-names>I</given-names></name></person-group>. <article-title>Targeting inflammation in hypertension.</article-title><source>Curr Opin Nephrol Hypertens</source>. <year>2023</year>; <volume>32</volume>:<fpage>111</fpage>&#8211;<lpage>117</lpage>.<pub-id pub-id-type="pmid">36476561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MNH.0000000000000862</pub-id><pub-id pub-id-type="pmcid">PMC9872860</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walker</surname><given-names>KA</given-names></name><name name-style="western"><surname>Basisty</surname><given-names>N</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>DM</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Ferrucci</surname><given-names>L</given-names></name></person-group>. <article-title>Connecting aging biology and inflammation in the omics era.</article-title><source>J Clin Invest</source>. <year>2022</year>; <volume>132</volume>:<fpage>e158448</fpage>.<pub-id pub-id-type="pmid">35838044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI158448</pub-id><pub-id pub-id-type="pmcid">PMC9282936</pub-id></mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferrucci</surname><given-names>L</given-names></name><name name-style="western"><surname>Fabbri</surname><given-names>E</given-names></name></person-group>. <article-title>Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty.</article-title><source>Nat Rev Cardiol</source>. <year>2018</year>; <volume>15</volume>:<fpage>505</fpage>&#8211;<lpage>522</lpage>.<pub-id pub-id-type="pmid">30065258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41569-018-0064-2</pub-id><pub-id pub-id-type="pmcid">PMC6146930</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murabito</surname><given-names>JM</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Larson</surname><given-names>MG</given-names></name><name name-style="western"><surname>Rong</surname><given-names>J</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H</given-names></name><name name-style="western"><surname>Benjamin</surname><given-names>EJ</given-names></name><etal/></person-group>. <article-title>Measures of biologic age in a community sample predict mortality and age-related disease: the Framingham offspring study.</article-title><source>J Gerontol A Biol Sci Med Sci</source>. <year>2018</year>; <volume>73</volume>:<fpage>757</fpage>&#8211;<lpage>762</lpage>.<pub-id pub-id-type="pmid">28977464</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/gerona/glx144</pub-id><pub-id pub-id-type="pmcid">PMC5946832</pub-id></mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>P</given-names></name><name name-style="western"><surname>Gollapalli</surname><given-names>K</given-names></name><name name-style="western"><surname>Mangiola</surname><given-names>S</given-names></name><name name-style="western"><surname>Schranner</surname><given-names>D</given-names></name><name name-style="western"><surname>Yusuf</surname><given-names>MA</given-names></name><name name-style="western"><surname>Chamoli</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Taurine deficiency as a driver of aging.</article-title><source>Science (New York, NY)</source>. <year>2023</year>; <volume>380</volume>:<fpage>eabn9257</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abn9257</pub-id><pub-id pub-id-type="pmcid">PMC10630957</pub-id><pub-id pub-id-type="pmid">37289866</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>